Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.

Home » Publications » Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.
TitleOngoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.
Publication TypeJournal Article
Year of Publication2024
AuthorsSitoe HMior, Oswald WE, Zita F, Fall M, Momade T, Adams MW, Flueckiger RM, McPherson S, Eyob S, Doan T, Lietman TM, Arnold BF, Wickens K, Gwyn S, Martin DL, Kasubi M, Boyd S, Bakhtiari A, Jimenez C, Solomon AW, Harding-Esch EM, Mwingira UJ, Ngondi JM
JournalSci Rep
Volume14
Issue1
Pagination22842
Date Published2024 Oct 15
ISSN2045-2322
KeywordsAntibodies, Bacterial, Child, Child, Preschool, Chlamydia trachomatis, Cross-Sectional Studies, Female, Humans, Infant, Male, Mozambique, Prevalence, Seroepidemiologic Studies, Trachoma
Abstract

Mozambique is making progress towards elimination of trachoma as a public health problem, but in some districts trachomatous inflammation-follicular (TF) prevalence remains above the 5% elimination threshold despite years of various interventions, including antibiotic mass drug administration. To characterize transmission in four districts, we incorporated testing of ocular infection and serology into routine trachoma impact surveys (TIS) in August 2022. We examined residents aged ≥ 1 year for trachoma and collected information on household water, sanitation, and hygiene. Among children aged 1-9 years, we tested conjunctival swabs for Chlamydia trachomatis nucleic acid and dried blood spots for C. trachomatis antibodies. We modeled age-dependent seroprevalence to estimate seroconversion rate (SCR). We examined 4841 children aged 1-9 years. TF prevalence ranged between 1.1 and 6.0% with three districts below the 5% threshold. PCR-confirmed infection prevalence ranged between 1.1 and 4.8%, and Pgp3 seroprevalence ranged between 8.8 and 24.3%. Pgp3 SCR was 1.9 per 100 children per year in the district with the lowest TF prevalence. Two other districts with TF 

DOI10.1038/s41598-024-71201-z
Alternate JournalSci Rep
PubMed ID39406720
PubMed Central ID2491032